TWI893039B - 透過循環腫瘤dna分析之分子疾病評估之方法及系統 - Google Patents

透過循環腫瘤dna分析之分子疾病評估之方法及系統

Info

Publication number
TWI893039B
TWI893039B TW109145799A TW109145799A TWI893039B TW I893039 B TWI893039 B TW I893039B TW 109145799 A TW109145799 A TW 109145799A TW 109145799 A TW109145799 A TW 109145799A TW I893039 B TWI893039 B TW I893039B
Authority
TW
Taiwan
Prior art keywords
tumor
individual
cancer
methylation
score
Prior art date
Application number
TW109145799A
Other languages
English (en)
Chinese (zh)
Other versions
TW202138566A (zh
Inventor
亞歷克斯 羅伯遜
尼爾 彼得曼
妮可 蘭伯特
哈路克 泰兹坎
羅西 史里瓦斯
彼得 喬治
傑森 克羅斯
Original Assignee
美商勒森特生物股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商勒森特生物股份有限公司 filed Critical 美商勒森特生物股份有限公司
Publication of TW202138566A publication Critical patent/TW202138566A/zh
Application granted granted Critical
Publication of TWI893039B publication Critical patent/TWI893039B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW109145799A 2019-12-24 2020-12-23 透過循環腫瘤dna分析之分子疾病評估之方法及系統 TWI893039B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962953368P 2019-12-24 2019-12-24
US62/953,368 2019-12-24
US202062993564P 2020-03-23 2020-03-23
US62/993,564 2020-03-23

Publications (2)

Publication Number Publication Date
TW202138566A TW202138566A (zh) 2021-10-16
TWI893039B true TWI893039B (zh) 2025-08-11

Family

ID=76575344

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109145799A TWI893039B (zh) 2019-12-24 2020-12-23 透過循環腫瘤dna分析之分子疾病評估之方法及系統

Country Status (8)

Country Link
US (1) US20230135171A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081665A4 (cg-RX-API-DMAC7.html)
JP (2) JP7897794B2 (cg-RX-API-DMAC7.html)
CN (1) CN115087749A (cg-RX-API-DMAC7.html)
AU (1) AU2020414737A1 (cg-RX-API-DMAC7.html)
CA (1) CA3165763A1 (cg-RX-API-DMAC7.html)
TW (1) TWI893039B (cg-RX-API-DMAC7.html)
WO (1) WO2021133993A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11078475B2 (en) 2016-05-03 2021-08-03 Sinai Health System Methods of capturing cell-free methylated DNA and uses of same
US12592321B2 (en) 2020-06-19 2026-03-31 University Health Network Cancer detection and classification using methylome analysis
CN118234871A (zh) * 2021-07-27 2024-06-21 牛津大学校长、教师和学者 与用于细胞游离dna的tet辅助吡啶硼烷测序相关的组合物和方法
US20230092508A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Methods for disease assessment using drain fluid
WO2023092097A1 (en) * 2021-11-19 2023-05-25 Foundation Medicine, Inc. Fragment consensus methods for ultrasensitive detection of aberrant methylation
CN114703284A (zh) * 2022-04-15 2022-07-05 北京莱盟君泰国际医疗技术开发有限公司 一种血液游离dna甲基化定量检测方法及其应用
KR102789317B1 (ko) * 2023-10-06 2025-04-02 (주)지놈포미 고심도 세포 유리 핵산 시퀀싱 기반의 질병 조기 검출 장치 및 방법
EP4790149A1 (en) * 2023-10-06 2026-08-12 Genome4Me, Inc. Apparatus and method for early disease detection based on high-depth cell-free nucleic acid sequencing
CN117987556B (zh) * 2024-02-23 2026-07-14 上海小荷医学检验实验室有限公司 用于确定肿瘤组织的目标CpG位点的甲基化水平的方法
CN118448038B (zh) * 2024-04-26 2026-07-24 天津大学 一种基于多组学动态ctDNA监测食管鳞状细胞癌疗效的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI758011B (zh) 2014-07-18 2022-03-11 香港中文大學 Dna混合物中之組織甲基化模式分析
JP2019521673A (ja) * 2016-06-07 2019-08-08 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア 疾患および状態の分析のためのセルフリーdnaメチル化パターン
CA3049457C (en) * 2017-01-20 2023-05-16 Sequenom, Inc. Methods for non-invasive assessment of copy number alterations
BR112019018272A2 (pt) 2017-03-02 2020-07-28 Youhealth Oncotech, Limited marcadores metilação para diagnosticar hepatocelular carcinoma e câncer
EP3776555A2 (en) * 2018-04-13 2021-02-17 Grail, Inc. Multi-assay prediction model for cancer detection
WO2019200410A1 (en) * 2018-04-13 2019-10-17 Freenome Holdings, Inc. Machine learning implementation for multi-analyte assay of biological samples
CA3101527A1 (en) * 2018-06-06 2019-12-12 Lexent Bio, Inc. Methods for fingerprinting of biological samples

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
期刊 Davis, AA, et. al. Early detection of molecular disease progression by whole-genome circulating tumor DNA in advanced solid tumors. medRxiv 25 November 2019
期刊 Horning, Aaron M et al. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. The Prostate vol. 75 Wiley 2015 1790-801
期刊 Moss, Joshua et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nature communications vol. 9 Nature Publishing Group 29 Nov. 2018

Also Published As

Publication number Publication date
JP2026049725A (ja) 2026-03-18
WO2021133993A2 (en) 2021-07-01
JP2023508947A (ja) 2023-03-06
TW202138566A (zh) 2021-10-16
JP7897794B2 (ja) 2026-07-30
AU2020414737A1 (en) 2022-07-14
US20230135171A1 (en) 2023-05-04
CN115087749A (zh) 2022-09-20
CA3165763A1 (en) 2021-07-01
WO2021133993A3 (en) 2021-09-30
EP4081665A2 (en) 2022-11-02
EP4081665A4 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
US20230135171A1 (en) Methods and systems for molecular disease assessment via analysis of circulating tumor dna
JP7851251B2 (ja) 遺伝子サンプリングにおける統計的バイアスの軽減
US20180357378A1 (en) Systems and methods for generating, visualizing and classifying molecular functional profiles
US20240410016A1 (en) Cd274 rearrangements as predictors of response to immune checkpoint inhibitor therapy
US20250019770A1 (en) Circulating tumor dna fraction and uses thereof
US20240110230A1 (en) Biomarkers for cancer treatment
US20250003009A1 (en) Fragment consensus methods for ultrasensitive detection of aberrant methylation
US20250201339A1 (en) Use of combined cd274 copy number changes and tmb to predict response to immunotherapies
US20240093304A1 (en) Alk fusion genes and uses thereof
US20250084482A1 (en) Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer
JP2024519782A (ja) がん治療のためのcd274変異
US20220392638A1 (en) Precision enrichment of pathology specimens
WO2025024258A2 (en) Ebv status as a predictor of response to immunotherapy
WO2025122504A1 (en) Esr1 mutations, esr1 co-occurring mutations, and uses thereof
EP4581170A2 (en) Methods for evaluating clonal tumor mutational burden
WO2025122856A1 (en) Use of fibroblast growth factor receptor 3 mutations and tumor mutational burden to predict response to immunotherapies
WO2025122500A1 (en) Esr1 gene fusions and uses thereof
WO2026030539A1 (en) Alk mutations and uses thereof
JP2025500916A (ja) 包埋剤を包埋試料から除去する方法